FDA inspection
Luoxin Aurovitas Pharma (Chengdu) Co., Ltd: FDA inspection ending Jun 16, 2026
FDA inspection 1325140 · Chengdu
Key facts
| Inspection ID | 1325140 |
|---|---|
| Firm | Luoxin Aurovitas Pharma (Chengdu) Co., Ltd |
| FEI number | 3019967180 |
| Address | Chengdu Cross-Strait Science And Technology Industrial Development Park, Wenjiang, No. 800 Haifa Road |
| City | Chengdu |
| Fiscal year | 2026 |
| Inspection end date | Jun 16, 2026 |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data